10-Q: Bioventus Inc. Reports First Quarter 2024 Results, Revenue Up 8.7%

Bioventus Inc. saw a revenue increase of 8.7% in the first quarter of 2024, despite a net loss from continuing operations.

Summary

• Bioventus Inc. reported a net sales increase of 8.7% to $129.5 million for the first quarter of 2024, compared to $119.1 million in the same period of 2023.
• The company experienced a net loss from continuing operations of $6.0 million, an improvement from the $100.0 million loss in the first quarter of 2023.
• Adjusted EBITDA for the quarter was $22.6 million, compared to $17.0 million in the prior year.
• U.S. net sales increased by 9.9%, driven by growth in Pain Treatments and Surgical Solutions, while International net sales remained relatively flat.
• Gross profit increased to $88.4 million, with a gross margin of 68.3%, up from 62.1% in the prior year.
• Selling, general, and administrative expenses decreased by 3.0%, primarily due to lower consulting and bad debt expenses.
• Research and development expenses decreased by 31.1%, mainly due to lower consulting and equity-based compensation costs.
• The company completed the sale of its Wound Business in May 2023, resulting in a $78.6 million impairment charge in the first quarter of 2023.
• Bioventus amended its credit agreement in January 2024 to modify certain financial covenants.
• The company received EU certification for its Exogen Bone Stimulation System in April 2024.

Sentiment

Score: 7

Explanation: The document shows positive revenue growth and improved profitability metrics, but the ongoing legal issues and net loss temper the overall sentiment. The company is showing signs of improvement but still faces challenges.

Positives

• The company experienced a significant increase in net sales, indicating strong demand for its products.
• Adjusted EBITDA improved year-over-year, suggesting better operational efficiency.
• Gross profit margin increased, reflecting improved profitability.
• Selling, general, and administrative expenses decreased, indicating better cost management.
• The company secured EU certification for its Exogen Bone Stimulation System, expanding its market reach.
• The company has successfully divested its Wound Business, allowing it to focus on core operations.

Negatives

• The company reported a net loss from continuing operations of $6.0 million, although this is an improvement from the prior year.
• Research and development expenses decreased, which could potentially impact future product development.
• The company had a significant impairment charge in the first quarter of 2023 related to the Wound Business divestiture.

Risks

• The company is subject to ongoing shareholder litigation, which could result in significant legal expenses and unfavorable outcomes.
• The company is dependent on a limited number of products, which could pose a risk if demand for these products declines.
• The company faces competition from other companies, some of which have greater resources.
• The company's long-term growth depends on its ability to develop and commercialize new products.
• The company is subject to extensive governmental regulation, and failure to comply could result in enforcement actions.
• The company's debt obligations and financial covenants could restrict its operations and future capital needs.
• The company's ability to maintain its competitive position depends on its ability to attract, retain and motivate its senior management team and highly qualified personnel.

Future Outlook

The company anticipates that current cash, cash equivalents, future cash flows from operating activities, and cash available under its credit facility will be sufficient to meet its anticipated cash needs for at least the next 12 months. The company may explore additional divestiture opportunities for non-core assets to improve its liquidity position.

Management Comments

• Management believes that Adjusted EBITDA is a useful indicator of operating performance and for planning purposes.
• Management believes the claims alleged in the shareholder litigation lack merit and intends to defend itself vigorously.
• Management believes that current cash, cash equivalents, future cash flows from operating activities and cash available under our 2019 Credit Facility will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the unaudited consolidated condensed financial statements included herein.

Industry Context

The medical device industry is highly competitive and subject to extensive regulation. Bioventus's performance is influenced by factors such as product acceptance, reimbursement policies, and technological advancements. The company's focus on minimally invasive treatments aligns with current trends in healthcare.

Comparison to Industry Standards

• Bioventus's revenue growth of 8.7% is a positive sign, but it is important to compare this to the growth rates of its direct competitors such as Stryker, Zimmer Biomet, and Medtronic, which also operate in the orthopedics and medical device space.
• The company's gross margin of 68.3% is relatively strong, but it should be compared to the gross margins of its peers to assess its competitive position. Companies like Smith & Nephew and NuVasive are good benchmarks for comparison.
• The company's adjusted EBITDA of $22.6 million is a positive indicator, but it is important to compare this to the EBITDA margins of its competitors to assess its profitability. Companies like Globus Medical and Orthofix are relevant comparables.
• The company's ongoing shareholder litigation is a concern, and it is important to monitor the outcomes of these cases and compare them to similar cases faced by other companies in the industry. Companies like Johnson & Johnson and Boston Scientific have faced similar legal challenges in the past.
• The company's debt levels and financial covenants should be compared to those of its peers to assess its financial health. Companies like Wright Medical and Integra LifeSciences are relevant comparables for debt analysis.

Legal Proceedings

• The company is involved in a putative class action lawsuit filed in the Middle District of North Carolina, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and of Sections 11 and 15 of the Securities Act.
• The company is also involved in two derivative shareholder lawsuits filed in the United States District Court for the District of Delaware, alleging violations of Section 14(a) of the Exchange Act, breaches of fiduciary duties and related state law claims.
• The company is involved in a lawsuit with Misonix's former distributor in China, which was affirmed in favor of Misonix by the Second Circuit Court of Appeals.
• The company was dismissed from a lawsuit filed by a minority shareholder of Bioness in the Delaware State Court of Chancery.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance, ongoing litigation, and strategic decisions.
• Employees are impacted by the company's restructuring plans and compensation policies.
• Customers are impacted by the company's product offerings and pricing.
• Suppliers are impacted by the company's purchasing decisions and contractual obligations.
• Creditors are impacted by the company's debt obligations and financial covenants.

Next Steps

• The company will continue to monitor the performance of its core businesses.
• The company will continue to manage its debt obligations and financial covenants.
• The company will continue to defend itself in ongoing shareholder litigation.
• The company will continue to explore additional divestiture opportunities for non-core assets to improve its liquidity position.

Key Dates

Keywords

Bioventus, medical devices, orthopedics, pain management, bone healing, surgical solutions, restorative therapies, EBITDA, net sales, financial results